| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 93,281 | 75,470 | ||
| Restricted cash | 0 | 0 | ||
| Marketable securities | 168,453 | 186,552 | ||
| Trade accounts receivable, net | 56,632 | 56,232 | ||
| Inventories | 51,649 | 49,487 | ||
| Prepaid expenses and other current assets | 18,474 | 15,084 | ||
| Total current assets | 388,489 | 382,825 | ||
| Deferred income tax assets, noncurrent | 38,393 | 35,765 | ||
| Property and equipment, net | 18,046 | 18,352 | ||
| Operating lease right-of-use assets | 11,158 | 16,387 | ||
| Goodwill | 16,698 | 16,707 | ||
| Intangible assets, net | 17,676 | 18,601 | ||
| Other noncurrent assets | 4,459 | 4,683 | ||
| Total assets | 494,919 | 493,320 | ||
| Trade accounts payable | 7,632 | 6,853 | ||
| Legal settlement liability, current | 2,177 | 1,968 | ||
| Accrued expenses | 20,233 | 21,604 | ||
| Other current liabilities | 16,426 | 14,717 | ||
| Deferred revenue, current | 28,739 | 28,128 | ||
| Total current liabilities | 75,207 | 73,270 | ||
| Legal settlement liability, noncurrent | 8,158 | 8,477 | ||
| Deferred revenue, noncurrent | 16,315 | 16,625 | ||
| Operating lease liability, noncurrent | 13,494 | 14,119 | ||
| Long term debt | 655 | 791 | ||
| Other noncurrent liabilities | 2,519 | 2,481 | ||
| Total liabilities | 116,348 | 115,763 | ||
| Common stock, 0.001 par value 1,000,000,000 authorized shares as of september 30, 2025 and december31, 2024, respectively 127,864,830 and 129,205,901 issued and outstanding shares as of september 30, 2025 and december31, 2024, respectively | 128 | 127 | ||
| Additional paid-in capital | 435,284 | 429,652 | ||
| Accumulated deficit | -57,662 | -52,184 | ||
| Accumulated other comprehensive gain | 821 | -38 | ||
| Total stockholders equity | 378,571 | 377,557 | ||
| Total liabilities and stockholders equity | 494,919 | 493,320 | ||
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)